Crossject Société Anonyme

Paris Stock Exchange ALCJ.PA

Crossject Société Anonyme Price to Sales Ratio (P/S) on January 14, 2025: 627.07

Crossject Société Anonyme Price to Sales Ratio (P/S) is 627.07 on January 14, 2025, a -55.56% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Crossject Société Anonyme 52-week high Price to Sales Ratio (P/S) is 1,411.00 on January 15, 2024, which is 125.01% above the current Price to Sales Ratio (P/S).
Crossject Société Anonyme 52-week low Price to Sales Ratio (P/S) is 390.32 on June 17, 2024, which is -37.76% below the current Price to Sales Ratio (P/S).
Crossject Société Anonyme average Price to Sales Ratio (P/S) for the last 52 weeks is 644.21.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Paris Stock Exchange: ALCJ.PA

Crossject Société Anonyme

CEO	Mr. Patrick Alexandre
IPO Date	Feb. 20, 2014
Location	France
Headquarters	6 Rue Pauline Kergomard
Employees	105
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.

Key trends

Past 5 years